Clinical trials: Intestinal Dysfunction
Bowel Dysfunction
An Evaluation of Navina Mini, a New Trans-anal Irrigation (TAI) Device in Children and Adolescents
The study is designed to deliver further information on clinical benefit, patients' satisfaction, and perception of handling and to confirm safety of Navina Mini when used in children and adolescents.
- Trial name
- NCT06385249
- Testing
- Navina Mini
- Where
- Sweden
- Volunteers
- 27 people
- Sponsor
- Wellspect HealthCare
Bowel Dysfunction
En Evaluation of Navina Mini, a New Low-volume Transanal Irrigation Device.
This is an un-controlled, prospective, multi center, post market clinical follow-up investigation that will enroll male and female subjects in need of bowel management with low-volume transanal irrigation (TAI) as judged by the…
- Trial name
- NCT06377280
- Testing
- Navina Mini
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Wellspect HealthCare
Bowel Dysfunction
Exploratory Investigation on a Novel Catheter
An exploratory, pre-market, open, prospective, interventional, clinical investigation at a limited number of centers for proof of concept of a new catheter.
- Trial name
- NCT05644912
- Testing
- Transanal irrigation (TAI)
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Wellspect HealthCare
Fecal Incontinence, Bowel Dysfunction
LIBERATE - PRO: Eclipse™ System Registry
A prospective, open label post market registry to collect Patient Reported Outcomes in an online data capture registry, maintained by Pelvalon, of women with fecal incontinence exiting the LIBERATE study (NCT02428595) continuing…
- Conditions
- Fecal Incontinence, Bowel Dysfunction, Bowel Incontinence, Accidental Bowel Leakage
- Trial name
- LIBERATEPRO (NCT03028636)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Pelvalon, Inc.
Bowel Dysfunction
Methylnaltrexone in Patients With Opioid-Induced Bowel Dysfunction
This is a double-blind, randomized, parallel group, dose ranging study of subcutaneous methylnaltrexone to be conducted in patients with advanced medical illness and poorly controlled opioid induced constipation.
- Trial name
- NCT01367574
- Testing
- SC MNTX
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation, Bowel Dysfunction
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain.
- Trial name
- NCT00101998
- Testing
- alvimopan
- Where
- 162 sites in United States, Argentina and 24 more
- Volunteers
- 233 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bowel Dysfunction, Constipation
Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1) to alvimopan or placebo.
- Trial name
- NCT00241722
- Testing
- Alvimopan
- Where
- 227 sites in United States, Australia and 15 more
- Volunteers
- 805 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cancer, Bowel Dysfunction
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in participants…
- Trial name
- NCT00135577
- Testing
- alvimopan
- Where
- 40 sites in United States, Canada and 11 more
- Volunteers
- 67 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bowel Dysfunction, Constipation
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo.
- Trial name
- NCT00256932
- Testing
- alvimopan
- Where
- 200 sites in United States, Austria and 8 more
- Volunteers
- 518 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bowel Dysfunction, Constipation
Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain
Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo.
- Trial name
- NCT00259922
- Testing
- Alvimopan, Alviompan
- Where
- 187 sites in United States, Australia and 10 more
- Volunteers
- 485 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)